Embryonic tumours of the central nervous system

Clinical and Translational Oncology

Volumn 7, Issue 5, 2005, Pages 219-227

  Gutiérrez, Aurora Navajas ^a   Álvarez, Ana Fernández Teijeiro ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL TRIAL; HUMAN; MEDULLOBLASTOMA; PATHOLOGY; REVIEW;

CENTRAL NERVOUS SYSTEM NEOPLASMS; CLINICAL TRIALS; HUMANS; MEDULLOBLASTOMA;

EID: 24044541082     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/BF02712821     Document Type: Review

References (42)

1. Giangaspero RJ, Perry RH, Kelly PJ, et al. In: Kleihues. P, Cavenee WK, editors. World Health Organization Classification of Tumours; Pathology and Genetics of Tumours of the Nervous System. Lyon. (France): International Agency for Research on Cancer IARC Press; 2000. p. 123-39.
2. Strother DR, Pollack IF, Fisher PG, et al. Tumors of the central nervous system. In: Pizzo PA, Poplack DG, editors. Principles and Practice of Pediatric Oncology. Philadelphia PA: Lippincott Williams and Wilkins; 2002. p. 751-824.
3. Kühl J, Doz F, Taylor R. En: Walker DA, Perilongo G, Punt JAG, Taylor RE, editors. Brain and spinal tumors of childhood Arnold. Oxford University Press Inc; 2004. p. 331-44.
4. Steliarova Foucher E, Stiller CH, Kaatssch, et al. Geographical patterns and time trends of cancer incidence and survival among children and adolescents in Europe since the 1970s (the ACCIS project): an epidemiological study. Lancet. 2004; 364: 2097-105.
5. Peris Bonet R, Giner Ripoll B, García Cano A. Registro Nacional de Tumores Infantiles (RNTI-SEOP). Estadísticas básicas 4. 1980-2001, Supervivencia 1980-1997. Valencia, Universidad de Valencia: 2003.
6. Giangaspero F, Rigobello L, Bodily M, et al. Large cell medulloblastoma: A distinct variant with highly aggressive behavior. Am J Surg Pathol. 1992; 16: 687-93.
7. Eberhart CG, Kepner JL, Goldthwait PT, et al. Histopathologic grading of medulloblastomas: A Pediatric Oncology Group Study. Cancer. 2002; 94: 552-60.
8. Eberhart CG, Burger PC. Anaplasia and grading in medulloblastomas: Brain Pathol. 2003; 13: 376-85.
9. Pomeroy SL, Tamayo P, Gaasenbeek M, et al. Prediction of central nervous System embryonal tumour outcome based on gene expression. Nature. 2002; 415: 436-42.
10. Mulhern RK, Palmer SL, Reddick WE, et al. Risk of young age for selective neurocognitive deficits in medulloblastoma are associated with White matter loss. J Clin Oncol. 2001; 19: 472-9.
11. Carrie C, Hoffstetter S, Gomez F, et al. Impact of targeting deviations on outcome in medulloblastoma: study of the French Society of Pediatric Oncology (SFOP). Int J Radiat Oncol Biol Phys. 1999; 45: 435-9.
12. Peet AC, Leach MO, Pinkerton CR, Price P, Williams SR, Grundy RG. Proccedings of the Engineering and Physical Sciences Research Council Workshop. The development of Functional imaging in the diagnosis, management and understanding of childhood brain tumours. Pediatr Blood Cancer. 2005; 44: 103-13.
13. Chang CH, Housepian EM, Herbert C. An operative staging system and a megavoltage radiotherapeutic technique for cerebellar meduloblastoma. Radiology. 1969; 93: 1351-9.
14. Zeltzer PM, Boyett JM, Finlay JL, et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastomas in children: conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol. 1999; 17: 832-45.
15. Fernández-Teijeiro A, Betensky RA, Sturla LM, et al. Combining gene expression profiles and clinical parameters for risk stratification in medulloblastomas. J Clin Oncol. 2004; 22: 994-8.
16. Gajjar A, Hernan R, Kocak M, et al. Clinical, histopathological and molecular markers of prognosis: Towards a new disease risk stratification for medulloblastoma. J Clin Oncol. 2004; 22: 984-93.
17. Gilbertson R, Wickramasinghe C, Hernan R, et al. Clinical and molecular stratification of disease risk in medulloblastoma. Brit J Cancer. 2001; 85: 705-12.
18. Grotzer MA, Janss AJ, Fung K, et al. TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumors. J Clin Oncol. 2000; 18: 1027-35.
19. Cvekl A Jr, Zavadil J, Birshtein BK, Grotzer MA, Cvekl A. Analysis of transcripts from 17p13.3 in medulloblastoma suggests ROX/MNT as a potential tumour suppressor gene. Eur J Cancer. 2004; 40 (16): 2525-32.
20. Taylor RE, Bailey CC, Robinson K, et al. Results of a randomised study of pre-radiotherapy chemotherapy vs radiotherapy alone for non-metastatic (M0-1) medulloblastoma. The SIOP/UKCCSG PNET-3 study. J Clin Oncol. 2003; 21: 1581-91.
21. Packer RJ, Goldwein J, Nicholson HS, et al. Treatment of children with medulloblastomas with reduced dose craniospinal radiation therapy and adjuvant chemotherapy: a Children's Cancer Group Study. J Clin Oncol. 1999; 17: 2127-36.
22. Packer RJ, Sutton LN, Elterman R, Lange B, Goldwein J, Nicholson HS. Outcome for children with medulloblastomas treated with radiation and cisplatin, CCNU and vincristine chemotherapy. J Neurosurg. 1994; 81: 690-8.
23. Grill J, Kieffer-Renaux V, Bulteau C, et al. Long term intellectual outcome in children with posterior fossa tumours according to radiation doses and volumes. Int J Radiat Oncol Biol Phys. 1999; 45: 137-45.
24. Tait DM, Thornton-Jones H, Bollom HJG, et al. Adjuvant chemotherapy for medulloblastoma: The first multicentre control trial of the International Society of Pediatric Oncology (SIOP I). Eur J Cancer. 1990; 26: 464-9.
25. Ellison DW, Clifford SC, Gajjar A, et al. Recent advances in medulloblastoma. Eur J Ped Neurol. 2003; 7: 53-66.
26. Kühl J. Modern treatment strategies in medulloblastoma. Childs Nerv Syst. 1998; 14: 2-5.
27. Kortmann RD, Kuhl J, Timmerman B, et al. Postoperative neoadjuvant chemotrerapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: Results of the German prospective randomized trial HIT' 91. Int J Radiat Oncol Biol Phys. 2000; 46: 269-79.
28. Rood BR, Macdonald TJ, Packer RJ. Current treatment of medulloblastoma: recent advances and future challenges. Semin Oncol. 2004; 31 (5): 666-75.
29. Blaney SM, Poplack DG, New cytotoxic drugs for intrathecal administration. J Neurooncol. 1998; 38: 219-23.
30. Slavc I, Schuller E, Czech T, Hainfellner JA, Seidl R, Dieckmann K. Intrathecal mafosfamide therapy for pediatric brain tumors with meningeal dissemination. J Neurooncol. 1998; 38: 213-8
31. Miralbell R, Bieri S, Huguenin P, et al. Prognostic value of cerebrospinal fluid cytology in pediatric medulloblastoma. Swis Pediatric Oncology Group. Ann Oncol. 1999; 10: 239-41.
32. Duffner PK, Horowitz ME, Krischer JP, et al. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumours. N Engl J Med. 1993; 328: 1725-31.
33. Duffner PK, Horowitz ME, Krischer JP, et al. The treatment of malignant brain tumours in infants and very young children: an update of the Pediatric Oncology Group experience. J Neuro Oncol. 1999; 1: 152-61.
34. Palmer SL, Goloubeva O, Reddick WE, et al. Patterns of intellectual development among survivors of pediatric medulloblastoma. A longitudinal analysis. J Clin Oncol. 2001; 19: 2302-8.
35. Reddy AT, Janss AJ, Phillips PC, Weiss HL, Packer RJ. Outcome for children with supratentorial primitive neuroectodermal tumors treated with surgery, radiation and chemotherapy. Cancer. 2000; 88 (9): 2189-93.
36. Timmerman B, Kortmann RD, Kühl, et al. The role of radiation therapy in the treatment of supratentorial PNET in childhood: results of the prospective German brain tumor trials HIT 88/89 and 91. J Clin Oncol. 2002; 20: 842-9.
37. Kalifa C, Valteau D, Pizer B, Vassal G, Grill J, Hartmann O. High dose chemotherapy in childhood brain tumours. Childs Nerv Syst. 1999; 15: 498-505.
38. Pérez A, Quintero V, González M, et al High-dose chemotherapy with autologous stem cell rescue in children with high-risk and recurrent brain tumors. An Pediatr. 2004; 61 (1): 8-15.
39. Chi SN, Gardner SL, Levy AS, et al. Feasibility and response to induction chemotherapy intensified with high-dose methotrexate for young children with newly diagnosed high-risk disseminated medulloblastoma. J Clin Oncol. 2004; 22: 4881-7.
40. Wolden SL, Dunkel IJ, Souweidane MM, et al. Patterns of failure using a conformal radiation therapy tumor bed boost for medulloblastoma. J Clin Oncol. 2003; 21: 3079-83.
41. Rutkowski S, Bode U, Deinlein F, et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med. 2005; 352: 978-86.
42. Gilbertson RJ. Medulloblastoma: signaling a change in treatment. Lancet Oncol. 2004; 5 (4): 209-18.